Morin

Morin

SCHEMBL2118429

O=c1c(O)c(-c2ccc(O)cc2O)oc2cc(O)cc(O)c12.O=c1c(O)c(-c2ccccc2)oc2ccccc12

nearest known ligand 0.75

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 11/20 0.75
KMT2A Q03164 11/20 0.75
CYP3A4 P08684 10/20 0.75
MAPT P10636 8/20 0.75
ABCB1 P08183 7/20 0.75
FTO Q9C0B1 6/20 0.75
CYP2C9 P11712 6/20 0.75
XDH P47989 5/20 0.75
CYP1B1 Q16678 5/20 0.75
CYP2D6 P10635 5/20 0.75
CYP2C19 P33261 5/20 0.75
CA12 O43570 4/20 0.75
TRPC5 Q9UL62 4/20 0.75
CYP1A1 P04798 4/20 0.75
CYP1A2 P05177 4/20 0.75
BCHE P06276 4/20 0.75
ACHE P22303 4/20 0.75
ADORA3 P0DMS8 3/20 0.75
PPARG P37231 3/20 0.75
CA7 P43166 3/20 0.75

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Galangin SCHEMBL7926038 0.94 MEN1 (0.85) MEN1KMT2ACYP3A4MAPTABCB1
Datiscetin SCHEMBL15675904 0.93 MEN1 (0.75) MEN1KMT2ACYP3A4MAPTABCB1
Kaempferol SCHEMBL31164054 0.93 MEN1 (0.79) MEN1KMT2ACYP3A4MAPTABCB1
Kaempferol SCHEMBL1485787 0.93 MEN1 (0.79) MEN1KMT2ACYP3A4MAPTABCB1
Myricetin SCHEMBL2278240 0.90 MEN1 (0.77) MEN1KMT2ACYP3A4MAPTABCB1
Kaempferol SCHEMBL731179 0.88 MEN1 (0.68) MEN1KMT2ACYP3A4MAPTABCB1
Quercetin SCHEMBL111510 0.88 MEN1 (0.76) MEN1KMT2ACYP3A4MAPTABCB1
Morin SCHEMBL6043175 0.87 FTO (0.65) MEN1KMT2ACYP3A4MAPTABCB1
Galangin SCHEMBL29393121 0.87 MEN1 (1.00) MEN1KMT2ACYP3A4MAPTABCB1
Galangin SCHEMBL117225 0.87 MEN1 (1.00) MEN1KMT2ACYP3A4MAPTABCB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008071416-A1 MORIN, A NEW INHIBITOR OF MICROBIAL HYALURONATE LYASE LEIBNIZ INSTITUTE FOR NATURAL PRODUCT RESEARCH AND INFECTION BIOLOGY E.V. HANS-KNÖLL-INSTITUT (HKI) (DE) 2008-06-19 WO claimed
EP-1932526-A1 Morin, a new inhibitor of microbial hyaluronate lyase Leibniz-Institut für Naturstoff-Forschung und Infektionsbiologie e.V. Hans-Knöll-Institut (DE) 2008-06-18 EP claimed
US-20230123785-A1 CRYPTIC METABOLITES AND METHOD FOR ACTIVATING SILENT BIOSYNTHETIC GENE CLUSTERS IN DIVERSE MICROORGANISMS THE TRUSTEES OF PRINCETON UNIVERSITY (US) 2023-04-20 US disclosed
US-11549950-B2 Cryptic metabolites and method for activating silent biosynthetic gene clusters in diverse microorganisms THE TRUSTEES OF PRINCETON UNIVERSITY 2023-01-10 US disclosed
US-20210041452-A1 CRYPTIC METABOLITES AND METHOD FOR ACTIVATING SILENT BIOSYNTHETIC GENE CLUSTERS IN DIVERSE MICROORGANISMS THE TRUSTEES OF PRINCETON UNIVERSITY (US) 2021-02-11 US disclosed
EP-3662053-A1 CRYPTIC METABOLITES AND METHOD FOR ACTIVATING SILENT BIOSYNTHETIC GENE CLUSTERS IN DIVERSE MICROORGANISMS The Trustees of Princeton University (US) 2020-06-10 EP disclosed
CN-111164202-A Recessive metabolites and methods for activating silent biosynthetic gene clusters in a variety of microorganisms 普林斯顿大学 2020-05-15 CN disclosed
WO-2019027877-A1 CRYPTIC METABOLITES AND METHOD FOR ACTIVATING SILENT BIOSYNTHETIC GENE CLUSTERS IN DIVERSE MICROORGANISMS THE TRUSTEES OF PRINCETON UNIVERSITY (US) 2019-02-07 WO disclosed
US-20150182472-A1 DENATURED LACTOGLOBULIN AND POLYPHENOL COASSEMBLIES TECHNION RESEARCH AND DEVELOPMENT FOUNDATION, LTD. (IL) 2015-07-02 US disclosed
US-9005664-B2 Denatured lactoglobulin and polyphenol coassemblies TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (IL) 2015-04-14 US disclosed
US-20120093933-A1 DENATURED LACTOGLOBULIN AND POLYPHENOL COASSEMBLIES TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (IL) 2012-04-19 US disclosed
WO-2008071416-A1 MORIN, A NEW INHIBITOR OF MICROBIAL HYALURONATE LYASE LEIBNIZ INSTITUTE FOR NATURAL PRODUCT RESEARCH AND INFECTION BIOLOGY E.V. HANS-KNÖLL-INSTITUT (HKI) (DE) 2008-06-19 WO disclosed
WO-2008071416-A1 MORIN, A NEW INHIBITOR OF MICROBIAL HYALURONATE LYASE LEIBNIZ INSTITUTE FOR NATURAL PRODUCT RESEARCH AND INFECTION BIOLOGY E.V. HANS-KNÖLL-INSTITUT (HKI) (DE) 2008-06-19 WO disclosed
EP-1932526-A1 Morin, a new inhibitor of microbial hyaluronate lyase Leibniz-Institut für Naturstoff-Forschung und Infektionsbiologie e.V. Hans-Knöll-Institut (DE) 2008-06-18 EP disclosed
EP-1932526-A1 Morin, a new inhibitor of microbial hyaluronate lyase Leibniz-Institut für Naturstoff-Forschung und Infektionsbiologie e.V. Hans-Knöll-Institut (DE) 2008-06-18 EP disclosed
EP-1100539-A2 COMBINATION OF ACTIVE SUBSTANCES, ESPECIALLY FOR THE PROPHYLAXIS AND THERAPY OF ISCHAEMIC ORGANIC LESIONS AND REPERFUSION SYNDROMES Vascular Biotech GmbH (DE) 2001-05-23 EP disclosed
WO-2000007578-A2 COMBINATION OF ACTIVE SUBSTANCES, ESPECIALLY FOR THE PROPHYLAXIS AND THERAPY OF ISCHAEMIC ORGANIC LESIONS AND REPERFUSION SYNDROMES VASCULAR BIOTECH GMBH (DE) 2000-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210041452-A1 CRYPTIC METABOLITES AND METHOD FOR ACTIVATING SILENT BIOSYNTHETIC GENE CLUSTERS IN DIVERSE MICROORGANISMS GLA, ERG28, SBK3 MEN1 2842/4885KMT2A 1729/4885CYP3A4 524/4885
US-11549950-B2 Cryptic metabolites and method for activating silent biosynthetic gene clusters in diverse microorganisms ERG28, SBK3, GLB1 MEN1 2304/4885KMT2A 1924/4885CYP3A4 1776/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.